Product

AZD9291 + Intermittent Selumetinib

Aliases

Osimertinib & ARRY-142886, Part A - AZD9291 in combination with intermittent selumetinib

1 clinical trial

1 indication

Indication

Clinical trial

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).

Status: Active (not recruiting), Estimated PCD: 2020-03-04